Carclo’s HY26: lower sales, fatter margins, stronger profits
Carclo’s half-year numbers are a neat example of “less can be more”. Revenue dipped 6.1% to £57.2m, but underlying operating profit jumped 61.2% to £5.5m as the portfolio reset, factory consolidation and tighter cost control flowed through. Statutory profit came in at £0.4m versus a £0.7m loss last year.
The quality metrics are moving in the right direction too. Return on Sales (ROS) on a trailing twelve-month basis hit 10.1% and Return on Capital Employed (ROCE) reached 28.8%, beating the Group’s medium‑term targets of 10% and 25% respectively. That matters because it shows the profit uplift is coming from structural improvements, not just a one‑off windfall.
Key numbers at a glance
| Measure | HY26 | HY25 (restated) | Change |
|---|---|---|---|
| Revenue | £57.2m | £61.0m | (6.1)% |
| Underlying operating profit | £5.5m | £3.4m | +61.2% |
| Underlying EBITDA | £8.6m | £7.1m | +22.3% |
| Underlying EPS (basic) | 0.9p | 0.6p | +50.0% |
| Statutory operating profit | £5.2m | £2.4m | +112.2% |
| Statutory diluted EPS | 0.5p | (0.9)p | — |
| Cash generated from operations | £3.9m | £7.3m | (45.7)% |
| Net debt | £24.5m | £25.2m | Improved |
Definitions in brief: underlying strips out significant one‑off items; EBITDA is earnings before interest, tax, depreciation and amortisation; ROS is operating margin; ROCE is operating profit divided by the capital invested in the business.
What drove the profit surge despite lower revenue?
Three big levers did the heavy lifting:
- Portfolio reset and site consolidation: US operations were consolidated into Pennsylvania and non‑core short‑run lines were exited last year. That turbocharged margins, with CTP division ROS up to 13.8% from 8.2%.
- Operational efficiency: better machine utilisation, cost discipline and standardised manufacturing platforms pushed Group underlying ROS to 9.6% (HY25: 5.6%).
- Mix shift: Speciality delivered stronger aerospace demand and improved margins at 21.6% (HY25: 19.8%).
There was a currency drag too. A stronger sterling knocked £1.5m from CTP revenue. On a like‑for‑like, constant currency basis, Manufacturing Solutions revenue across CTP and Speciality was 5.8% higher, which underlines the operational progress.
Divisional performance: CTP, D&E and Speciality
CTP Manufacturing Solutions
CTP revenue was £49.3m, down 8.7%, but that headline masks the exit of non‑core US activities and FX translation. On a like‑for‑like basis, Manufacturing Solutions grew 4.5%. The US business is now showing underlying sales growth and better margins following consolidation. EMEA remained steady with solid margins, China outperformed, and India was softer due to a key customer, with new wins expected to catch up in H2.
CTP Design & Engineering (D&E)
D&E revenue fell 43.6% to £4.0m on lower US customer activity. EMEA project work rose 21.9% and management expects a small H2 uptick. This unit remains important for tooling and process design that supports the global manufacturing platform, but near‑term revenue is volatile.
Speciality division
Speciality revenue rose 14.1% to £8.0m, driven by aerospace and share gains in specialist machining. Margin expanded to 21.6%. Capacity is being added, including a new CNC machine in France to support growth.
Cash flow, debt and the pension: the less glossy bits
Operating cash generation was £3.9m, down from £7.3m, as working capital normalised from an unusually low year‑end and US customer payment terms shifted under the new financing. Net cash from operations was £0.4m after interest (£1.7m), tax (£0.5m) and pensions (£1.3m).
Net debt sits at £24.5m, modestly lower year on year, though up since March due to the one‑off £5.1m pension contribution agreed as part of April’s refinancing. The new three‑year BZ facility totals £36.0m comprising a £27.0m term loan and a £9.0m revolving credit facility, priced over SONIA/SOFR/€STR with margins ranging from 4.5% to 7.5% depending on the asset bucket. Finance costs rose to £3.7m, including £1.4m of pension interest.
The defined benefit scheme remains material but improved. The IAS 19 liability reduced to £44.7m from £51.7m at March, helped by asset gains and the £5.1m payment. On technical provisions, the deficit is estimated at £52.7m at 30 September 2025. A recovery plan is in place with £3.5m annual contributions to 2029, then £5.8m (indexed) to 2037. No interim dividend has been declared and, with insufficient distributable reserves, dividends are off the table for now.
Safety, contracts and strategy
Health and safety continues to improve with the Incident Frequency Ratio at 0.6 (HY25: 1.3). In July, Carclo announced a significant five‑year contract renewal with a major customer, which should help revenue visibility. Strategically, the Group is pressing its shift from volume supply to higher‑value, precision engineered solutions in Life Sciences, Aerospace and Safety & Security, manufactured in‑region for in‑region supply.
Outlook: guidance unchanged, margins to keep edging up
The Board’s full‑year expectations are unchanged. Management expects D&E revenue to tick up slightly in H2, continued margin expansion and positive cash generation. Medium‑term emphasis is on deepening positions in Life Sciences and sustaining growth in Speciality, particularly aerospace.
Principal risks remain familiar: supply chain and geopolitical disruption, customer concentration, and the drag from high interest rates. Mitigations include stronger procurement, operating efficiencies, higher asset utilisation and a focus on debt reduction.
My take: structurally better, with a few watch‑outs
On balance, this is a positive half. The big story is margin quality: ROS at 10.1% TTM and ROCE at 28.8% show the portfolio reset is landing. Speciality is delivering, and the CTP manufacturing core is grinding out efficiency gains despite FX headwinds and softer D&E.
Why it matters for shareholders
- Profit growth is coming from repeatable operational improvements, not just cost cuts that cannot be repeated.
- US restructuring is translating into tangible margin gains, which historically has been the swing factor.
- The contract renewal supports multi‑year visibility, helpful when the order book is concentrated.
What to keep an eye on
- Cash conversion: working capital should settle, but it bears watching after the HY dip.
- Finance and tax costs: net finance expense at £3.7m and a 75.1% statutory effective tax rate weigh on bottom‑line EPS.
- Pension and leverage: the scheme is moving the right way, yet it still commands cash and contributes to interest costs.
- D&E recovery: a small H2 uplift is guided, but US activity needs to re‑accelerate.
In short, Carclo looks a tighter, higher‑return business than a year ago. If management sustains mid‑teens divisional margins and keeps chipping away at debt and the pension, the earnings profile should continue to improve. The near‑term swing factors are cash conversion in H2 and the pace of D&E stabilisation.
